title: Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.
abstract: Cancer stem cells (CSCs) are recently discovered as vital obstacles for the successful cancer therapy. Emerging evidences suggest that miR-200c functions as an effective CSCs inhibitor and can restore sensitivity to microtubule-targeting drugs. In the present work, the intelligent gelatinases-stimuli nanoparticles (NPs) was set up to co-deliver miR-200c and docetaxel (DOC) to verify their synergetic effects on inhibition of CSCs and non-CSC cancer cells. After tumor cells were treated with miR-200c NPs, miR-200c and its targeted gene class III beta-tubulin (TUBB3)TUBB3 expression were evaluated. The effects of miR-200c/DOC NPs on tumor cell viability, migration and invasion as well as the expression of E-cadherin and CD44 were studied. The antitumor effects of miR-200c/DOC NPs were compared with DOC NPs in xenograft gastric cancer mice. Moreover, the residual tumors after treatment were subcutaneously seeded into nude mice to further investigate the effective maintenance of NPs. We found that the gelatinases-stimuli NPs facilitated miR-200c into cells, achieving sustained miR-200c expression in tumor cells during 9 days. The miR-200c/DOC NPs significantly enhanced cytotoxicity of DOC, possibly by decreasing TUBB3 level, and reversing EMT. The miR-200c NPs achieved high levels of in vivo accumulation and long retention in gastric cancer xenografts after intravenous administration. The miR-200c/DOC NPs prominently suppressed in vivo tumor growth with elevated miR-200c and E-cadherin levels and down-regulated TUBB3 and CD44 expressions. When the residual tumors after miR-200c/DOC NPs treatment were re-transplanted into nude mice, the tumors demonstrated the slowest growth speed. The miR-200c/DOC NPs may provide a promising modality for co-delivery of nucleic acid and drugs to simultaneously inhibit CSCs and non-CSC cancer cells.
authors.affiliation: The Comprehensive Cancer Center of Drum-Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Zhongshan Road 321, Nanjing 21008, PR China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Liu
authors.forename: Ru-Tian
authors.initials: RT
authors.lastname: Li
authors.forename: Han-Qing
authors.initials: HQ
authors.lastname: Qian
authors.forename: Jia
authors.initials: J
authors.lastname: Wei
authors.forename: Li
authors.initials: L
authors.lastname: Xie
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Mi
authors.initials: M
authors.lastname: Yang
authors.forename: Xiao-Ping
authors.initials: XP
authors.lastname: Qian
authors.forename: Li-Xia
authors.initials: LX
authors.lastname: Yu
authors.forename: Xi-Qun
authors.initials: XQ
authors.lastname: Jiang
authors.forename: Bao-Rui
authors.initials: BR
authors.lastname: Liu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000077143:Docetaxel; D016503:Drug Delivery Systems; D005753:Gastric Mucosa / Q000378:metabolism; D018093:Gelatinases / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D035683:MicroRNAs / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use; D053758:Nanoparticles / Q000378:metabolism*; D014411:Neoplastic Stem Cells / Q000187:drug effects; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000627:therapeutic use; D014404:Tubulin / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C533896:MIRN200 microRNA, human; D035683:MicroRNAs; C498585:TUBB3 protein, human; D043823:Taxoids; D014404:Tubulin; D000077143:Docetaxel; D018093:Gelatinases